AIS Healthcare is one of the leading diagnostic and treatment services providers for all cancers, immunodeficiency, and heart diseases. World Health Organization has recognized the company as a top-ranking hospital in international healthcare rankings. AIS Healthcare is a global leader in innovative treatments for oncology, HIV/AIDS, cancer vaccines, and transplantation.
AIS has secured a unique position in the world market and domestically with its commitment to excellence and rigorous quality through strict monitoring of adherence to WHO standards. With more than thirty years of experience and expertise, they have established their presence worldwide with two operational clinics in Nigeria and Cameroon, where they are currently expanding operations.
The company has recently obtained a five-year strategic framework agreement with Nigeria’s National Agency for the Regulation of Drugs (NARD) to treat patients with cancer and HIV/AIDS and organ transplantation.
AIS is a multinational healthcare corporation based in Lagos and the United Kingdom that provides oncology, internal medicine, and other diagnostic services. The company was founded in 1992 by Ahmadu Adamu Danladi as an independent charity organization. AIS is a provider of healthcare services to patients across Africa.
AIS has state-of-the-art technology and treatment based on the standards accepted by the World Health Organization. AIS Healthcare is one of Nigeria’s first hospitals to offer interventional Cardiology, Nuclear Medicine, Molecular Diagnostics, Radiation Therapy, and Organ Transplantation.
AIS provides laboratory services for virology, microbiology, clinical chemistry (chemistry), hematology (blood test), immunology (test for immune system disorders), cytology (occult smears for diagnosis of abnormal cells), drug sensitivity testing, molecular diagnostics, molecular biology, and tissue histopathology. AIS also offers stem cell transplantation services for treating certain cancers in Nigeria. These include lymphoma, hematological malignancies (blood cancer), multiple myeloma (bone marrow cancer), sarcoma, breast cancer, colon cancer, liver cancer, and genitourinary system tumors.
AIS is one institution that participates in oncology clinical trials run by European drug regulators. In 2004 they set up a clinical trials section to ensure it complies with all Nigerian regulatory standards. They are currently looking at establishing a contract research-based organization to provide pharmaceutical companies with preclinical and clinical drug.